Is Sheep’s Blood Antivenom? How It’s Actually Made

Sheep’s blood is not antivenom, but it is one of the key raw materials used to produce it. The process involves immunizing sheep with small, escalating doses of snake venom over weeks or months, then collecting their blood plasma, which is now rich in venom-targeting antibodies. Those antibodies are extracted, enzymatically cut into smaller fragments, and purified before they become the medicine injected into a snakebite victim. The distinction matters: raw blood drawn from a sheep would be useless and dangerous to inject into a person, but the refined antibody fragments derived from that blood can save lives.

Why Sheep Enter the Picture at All

Antivenom production has relied on large animals since the 1890s, when researchers first discovered that animals repeatedly exposed to small amounts of toxin develop a robust immune response, and that the serum from those animals could protect others from lethal doses. Albert Calmette, working in the late nineteenth century, demonstrated that immunized animals’ serum was antitoxic in laboratory tests and could protect rabbits when given before or after venom injection.¹ For over a century, horses have been the default animal for this work, largely because they are big, produce high volumes of blood, and tolerate repeated immunization well. Sheep entered the field as an alternative host, and they have proven especially useful for certain venom types and product formats.

The core principle is the same regardless of the animal species. You inject the animal with venom in doses too small to cause serious harm but large enough to trigger an immune response. Over time, you increase the dose. The animal’s immune system produces antibodies that recognize and bind to the toxic proteins in the venom. After several rounds of immunization, the animal’s blood plasma is loaded with these venom-specific antibodies, and that plasma becomes the starting material for antivenom manufacturing.²

From Blood Draw to Medicine

Once the immunized sheep’s plasma is collected, it goes through a multi-step industrial process that transforms it from a biological fluid into a pharmaceutical product. The first step is isolating the immunoglobulin fraction, the portion of the plasma that contains the antibodies. This is typically done by precipitating the immunoglobulins out of the plasma using a salt like sodium sulfate or ammonium sulfate, which causes the antibodies to clump together so they can be separated from the rest of the plasma proteins.³

The next step is where sheep-derived antivenoms often diverge from older horse-derived products. Rather than using whole antibodies, manufacturers typically digest the immunoglobulins with an enzyme called papain, which cuts each antibody molecule into smaller pieces known as Fab fragments. These Fab fragments retain the part of the antibody that actually grabs onto venom toxins, but they shed the bulkier “tail” portion of the molecule (called the Fc region). One established process for cobra antivenom, for example, uses papain digestion followed by ammonium sulfate precipitation and column chromatography to isolate and purify the Fab fragments.⁴ Some manufacturers use a different enzyme, pepsin, to produce slightly larger fragments called F(ab’)₂, which are essentially two Fab units still linked together.

An alternative purification approach uses caprylic acid, a fatty acid that selectively precipitates unwanted proteins while leaving the antibodies intact. Research on ovine (sheep) antiserum has shown that caprylic acid does not interfere with the activity of papain or pepsin, meaning manufacturers can combine the purification and digestion steps more efficiently.⁵ For some products, an additional affinity chromatography step is used afterward: the Fab fragments are passed through a column containing immobilized snake venom, and only the fragments that physically bind to venom components are retained. This produces a highly specific antivenom with minimal non-functional protein.³

Why Cut Antibodies Into Fragments

There is a practical reason for chopping antibodies apart rather than using them whole. The Fc tail of an antibody molecule is what the human immune system is most likely to recognize as foreign. When you inject whole antibodies from a horse or sheep into a person, the Fc region can trigger allergic reactions, including potentially serious ones like serum sickness or anaphylaxis. By removing the Fc portion and keeping only the venom-binding Fab fragments, manufacturers reduce the risk of these adverse reactions while preserving the therapeutic effect.

Fab fragments also have a smaller molecular size, which means they distribute through the body more quickly and can reach venom molecules in tissue more easily. The tradeoff is that smaller fragments are also cleared from the bloodstream faster by the kidneys. This creates a clinical problem: the antivenom can wear off before all the venom in the patient’s body has been neutralized, allowing symptoms to return. Recurrence of local swelling and blood-clotting problems has been well documented after treatment with Fab antivenom for North American pit viper bites, and managing it requires repeated dosing over at least 18 hours with careful follow-up monitoring.⁶ Delayed or recurrent blood-clotting abnormalities can appear days after treatment, making follow-up beyond three days necessary to catch all cases.⁷

F(ab’)₂ fragments, being larger, are cleared more slowly than Fab fragments, which can reduce the recurrence problem. But they retain slightly more foreign protein, which may increase the chance of adverse reactions. The choice between Fab, F(ab’)₂, and whole IgG is a balancing act between efficacy, duration of action, and safety, and different manufacturers land on different answers depending on the venom and the target market.⁸

Sheep Versus Horses

Most antivenom worldwide is still made from horse plasma. Out of eight current and pending producers of sub-Saharan African antivenoms surveyed in one market analysis, only one uses ovine (sheep) antisera instead of equine.⁹ But research comparing the two has found that sheep antibodies can outperform horse antibodies against certain venoms. In one head-to-head comparison, ovine antivenoms raised against the venom of the South American rattlesnake were more effective than equine antivenoms at preventing death in mice, and they also did a better job of inhibiting the venom’s ability to break down red blood cells, trigger platelet clumping, and disrupt blood clotting. Sheep antisera for several other snake species, including the saw-scaled viper and European adder, similarly outperformed horse-derived products. The ovine antivenoms generally contained a higher concentration of venom-specific antibodies.¹⁰

That said, horses won for some species in the same study. The equine antivenoms against the monocled cobra and the western diamondback rattlesnake were more protective than their ovine counterparts. So the “better” host animal depends partly on which snake you’re immunizing against. Sheep are not a universal upgrade over horses; they are a useful alternative that outperforms in many but not all matchups.

A flock of sheep used for antivenom production can maintain high levels of venom-specific antibodies over long periods. One study immunizing sheep with a mixture of venoms from four different snake species found that all 25 sheep responded quickly and sustained strong antibody levels throughout the two-year study period.¹¹

CroFab and Real-World Sheep-Derived Antivenoms

The most widely known sheep-derived antivenom in clinical use is CroFab (Crotalidae Polyvalent Immune Fab, Ovine), used in the United States and other countries for pit viper bites, including rattlesnakes, copperheads, and cottonmouths. CroFab is produced by immunizing sheep with venoms from four snake species, then processing the plasma into purified Fab fragments. An antivenomics study of CroFab’s performance against prairie rattlesnake venom found that the product effectively removed many, though not all, of the major venom compounds.¹² That incomplete neutralization is a general challenge in antivenom design: snake venom is a complex cocktail of dozens of different toxic proteins, and no single antivenom product neutralizes every one equally well.

An earlier sheep-derived Fab product was developed specifically for European adder bites. Clinical trials of those specific sheep Fab fragments in patients bitten by the European adder found the treatment to be safe and effective at counteracting the effects of envenomation.¹³

Adverse Reactions and Who Is at Higher Risk

Even purified, fragment-based antivenoms can trigger adverse reactions. These range from mild symptoms like itching and hives to more serious reactions involving low blood pressure, difficulty breathing, or anaphylaxis. The overall incidence is relatively low: in one study of over 230 snakebite victims treated in Nigeria, about 12% experienced early adverse reactions.¹⁴

An interesting finding from that same study is that prior exposure to animal proteins can matter. Fulani herders, who have regular close contact with livestock, were nearly six times more likely to have an early adverse reaction than non-herding, non-Fulani patients. The likely explanation is that people who are regularly exposed to animal proteins through their occupation can develop sensitization, so when they receive an injection of animal-derived antibody fragments, their immune system reacts more aggressively. This is a factor that rarely gets discussed in general snakebite literature, but it matters for populations in rural areas of sub-Saharan Africa and South Asia where both snakebites and livestock herding are common.

Quality Control and Potency Testing

Finished antivenom products undergo strict quality testing before they can be used clinically. A third-generation antivenom developed in Colombia for coral snake bites illustrates the typical quality checks: the product had to demonstrate full solubility in under five minutes, a protein concentration around 31 milligrams per milliliter, purity over 98.5% for its F(ab’)₂ fragments, and no toxicity in mice at the tested doses. The potency testing showed that a single 10-milliliter vial could neutralize roughly 2.3 milligrams of one coral snake venom and about 4 milligrams of another.¹⁵ Those numbers might sound small, but a single snakebite often delivers only a few milligrams of venom, and multiple vials can be administered.

Potency testing itself is an area of active debate in the field. The standard method still relies on injecting mice with venom-antivenom mixtures and measuring survival, a technique largely unchanged since the early twentieth century. Efforts to develop alternative assays that reduce or replace animal testing are underway, but validated replacements have been slow to gain regulatory acceptance.

The Global Access Problem

Antivenom is one of the most neglected medicines in global health. Snakebite kills an estimated 80,000 to 140,000 people per year, mostly in rural areas of sub-Saharan Africa and South Asia. The manufacturing process described above is inherently expensive: it requires maintaining flocks of immunized animals, collecting and processing plasma under pharmaceutical-grade conditions, performing extensive quality testing, and cold-chain distribution to remote clinics. Analysis of the sub-Saharan African market found that most manufacturers produce polyspecific products designed to cover several snake species at once, and the majority use F(ab’)₂ fragments rather than whole IgG or Fab.⁹ Several manufacturers offer freeze-dried (lyophilized) products, which are easier to store and ship in hot climates without refrigeration, but this adds another processing step and cost.

The economic challenge is circular. Low demand forecasts discourage investment in production. Limited production keeps prices high. High prices push the product beyond the reach of the patients who need it most, which suppresses demand further. Multiple manufacturers have exited the African market entirely because it was not profitable. When one major producer stopped distributing its product in Africa in the early 2010s, some regions experienced severe shortages.

What Comes After Sheep and Horses

The entire model of hyper-immunizing large animals and harvesting their antibodies is being challenged by newer biotechnologies. The most striking recent advance involves nanobodies, miniature antibody fragments naturally produced by camelids like alpacas and llamas. A 2025 study immunized an alpaca and a llama with venoms from 18 different African snake species, then used molecular biology techniques to identify high-affinity nanobodies from their immune cells. The researchers combined just eight of these nanobodies into a defined mixture that effectively prevented death in mice exposed to the venoms of 17 different African elapid species, including cobras, mambas, and rinkhals. The recombinant antivenom outperformed a currently used plasma-derived product and also reduced tissue damage caused by cytotoxic venoms.¹⁶

Recombinant approaches like these could eventually eliminate the need for large-scale animal immunization entirely. Once you identify the right nanobodies, you can produce them in bacteria or yeast in a bioreactor, the same way insulin and many other biologics are manufactured today. The potential advantages are enormous: defined composition instead of batch-to-batch variation, no dependency on animal husbandry, easier quality control, potentially lower cost at scale, and the possibility of engineering nanobodies that are more potent or broader-spectrum than anything an animal’s immune system would naturally produce.

That said, recombinant antivenoms remain experimental. Getting them through clinical trials, regulatory approval, and scaled manufacturing will take years. In the meantime, immunized sheep and horses remain the backbone of antivenom production worldwide, and the painstaking process of venom collection, animal immunization, plasma harvesting, enzymatic digestion, and purification continues to be the only proven route from snakebite to survival for the vast majority of patients.